September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
October 2024 in “Clinical and Experimental Dermatology” The combination treatment didn't work better than minoxidil alone and caused more menstrual issues.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
38 citations
,
August 2015 in “Drug Design Development and Therapy” Topical flutamide works as well as hydroquinone for melasma but needs more safety checks.
43 citations
,
July 2018 in “Journal of The European Academy of Dermatology and Venereology” Finasteride and minoxidil mix works better for hair growth than minoxidil alone, with similar safety.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
21 citations
,
September 2013 in “Current medicinal chemistry” HAC and BAC improve skin targeting and reduce diffusion without causing irritation.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
April 2011 in “Reactions Weekly” January 2022 in “Drugs of Today” 59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
January 2021 in “International Journal of Advanced Research in Medicine” Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
September 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” D-004 shows moderate antidepressant effects but is less effective than Sertraline and Imipramine.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
30 citations
,
August 2010 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
25 citations
,
July 2022 in “Pharmaceutics” Spanlastic nanovesicles can improve efinaconazole delivery through nails.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.